Precigen (NASDAQ: PGEN) Surges on Strong Analyst Ratings and AdenoVerse Platform Potential

• Analyst firms like B. Riley, HC Wainwright, Zacks Research, and Wall Street Zen have issued "Buy" or "Strong-Buy" ratings for Precigen, with price targets increasing to $18.00.
• The U.S. Food and Drug Administration (FDA) granted its AdenoVerse platform a platform technology designation, potentially accelerating the development of new therapies for HPV-related cancers.
• Precigen's commercial product, Papzimeos, generated $74.6 million in revenue in the first half of 2026, providing a strong financial base for future pipeline development.

Precigen (NASDAQ: PGEN) is a biotechnology company focused on developing gene and cell therapies. The company generates revenue from its commercial product, Papzimeos, which is used to treat certain medical conditions. It also works on future growth through its AdenoVerse platform, which is designed to create new treatments for various diseases.

On September 25, 2026, analyst firm B. Riley started covering Precigen with a "Buy" rating. At the time of the rating, the stock price was $7.70. This follows a period of strong performance where the stock reached a new 52-week high of $8.04 and had a daily trading volume of over 5.3 million shares.

Other analysts also show interest in the company. As highlighted by HC Wainwright, the firm increased its price objective on Precigen from $14.00 to $18.00. Similarly, Zacks Research and Wall Street Zen upgraded the stock to a "strong-buy" rating. However, Weiss Ratings maintains a "sell (d-)" rating, providing a different perspective.

A key factor driving this attention is the company's AdenoVerse platform. The U.S. Food and Drug Administration (FDA) recently granted it a platform technology designation. This can help speed up the development of new therapies for HPV-related cancers by using existing manufacturing and preclinical data from current products.

The company's existing operations provide a strong financial base. The Papzimeos franchise is gaining commercial momentum, generating $74.6 million in revenue in the first half of 2026. With a current market capitalization of approximately $2.75 billion, Precigen is leveraging its current success to fund its future pipeline.